[Bactericidal activity of GLL-37, a novel derivative of the human antimicrobial peptide LL-37].
Shi. Lin L; Liu. Shan S; Fan. Gui-xiang GX; Yuan. Yu-kang YK; Mei. Long L
Key Findings
- GLL‑37 is more resistant to degradation by elastase than LL‑37
- GLL‑37 shows stronger antibacterial activity than LL‑37 under high‑salt conditions
- Both peptides retain bactericidal activity against a range of Gram‑positive and Gram‑negative bacteria
Practical Outcomes
- The findings suggest GLL‑37 could become a more stable antimicrobial agent for future therapies, but it’s not yet ready for personal use or dosing guidance. For biohackers, the main takeaway is that peptide stability matters, and current research is still at the early drug‑development stage.
Summary
Researchers made a new version of the human antimicrobial peptide LL‑37 called GLL‑37. It breaks down less when exposed to the enzyme elastase and works better than regular LL‑37 in salty environments, while still killing bacteria.
Abstract
To develop and investigate GLL-37, a substitution analogue of the human antimicrobial peptide LL-37 with anti-enzymatic degradation activity and improved efficacy. The bactericidal activities of LL-37 and newly developed GLL-37 against 6 Gram-negative and -positive bacteria were determined by Broth microdilution assays. The minimum inhibitory concentrations of LL-37 and GLL-37 against E.coli ATCC 25922 in different NaCl concentration medium were also detected. Both peptides were co-incubated with elastase, and then analyzed by PAGE electrophoresis and bactericidal activity determination. GLL-37 showed a stronger elastase resistance ability than LL-37, and was significantly more effective than LL-37 under high-salt condition. The antimicrobial peptide GLL-37 derived form LL-37 has the potential as a new therapeutic agent for bacterial infections.
Study Information
pubmed
2008
10.3785/j.issn.1008-9292.2008.01.013